Casi pharmaceuticals, inc. (CASI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Product sales

3,372

-

2,749

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease income

34

-

38

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product sales

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

23

23

23

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

669

0

0

0

1,932

0

8

0

-

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Total revenues

3,406

1,344

2,787

0

0

0

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,932

0

8

0

-

-

Costs and expenses:
Costs of revenues

3,211

-

2,648

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

3,017

-

1,829

2,979

2,567

-

1,806

1,729

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product sales

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

0

2

6

7

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

1,697

3,847

970

1,727

1,049

1,250

1,013

1,362

1,018

1,044

942

1,223

865

784

697

724

559

554

779

836

506

494

623

696

561

405

703

949

1,398

1,291

1,011

General and administrative

4,058

6,666

7,977

6,982

5,710

5,746

6,905

4,042

1,303

1,194

625

691

644

1,418

676

1,914

765

661

673

857

924

823

1,150

891

891

754

662

1,015

629

535

564

601

1,096

521

556

719

1,253

691

770

Selling and marketing

1,260

-

975

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Gain) loss on disposal of intangible assets

450

-

-

-

-48

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

1,081

-

0

5,848

0

-

0

0

686

0

0

0

0

-

-

-

-

-

-

-

-

-

19,681

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

3,000

Total cost and expenses

12,177

13,524

13,429

15,810

8,325

9,020

8,711

5,771

3,687

5,042

1,596

2,418

1,693

2,668

1,690

3,277

1,783

1,704

1,616

2,083

1,796

1,614

21,528

1,616

1,451

1,308

1,442

1,852

1,136

1,029

1,187

1,297

1,657

927

1,260

1,669

2,651

1,983

4,781

Loss from operations

-8,771

-

-10,642

-

-8,325

-

-8,711

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-operating income/(expense):
Interest income, net

190

278

414

320

49

9

11

13

6

1

-0

-0

0

-2

-5

-8

-8

-8

-24

-24

-24

-24

-2

0

0

0

0

0

0

-

0

-9,165

-

-

-

-

-

-

-

Foreign exchange gains

363

-452

719

479

71

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of investment in equity securities

15

-67

160

240

-45

252

56

101

-89

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-8,233

-12,281

-9,669

-15,251

-8,160

-9,264

-8,756

-5,859

-3,590

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Less: (loss)/ income attributable to redeemable noncontrolling interest

-109

-447

-23

61

14

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion to redeemable noncontrolling interest redemption value

317

-

-

-

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent rights

-

-

-

-

-

-

-

-

-

7

16

-10

6

2

-2

5

1

-10

-35

11

6

-18

6

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest (income) expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

875

0

0

0

0

106

168

Other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-48

2

55

-5

5

Net loss attributable to CASI Pharmaceuticals, Inc.

-8,441

-12,895

-9,646

-15,313

-8,177

-9,264

-8,756

-5,859

-3,590

-5,047

-1,613

-2,408

-1,700

-2,673

-1,693

-3,291

-1,794

-1,702

-1,604

-2,095

-1,803

-1,596

-21,538

-1,616

-1,450

-1,308

-1,442

-1,851

-1,135

-360

-1,187

-10,463

-2,533

1,004

-1,308

-1,658

-2,596

-2,095

-4,944

Dividends on Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

83

251

251

251

251

251

251

251

Net loss attributable to common shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-360

-1,187

-10,546

-2,785

753

-1,559

-1,909

-2,847

-2,346

-5,195

Net loss per share (basic and diluted) (in dollars per share)

-0.09

-0.13

-0.10

-0.16

-0.09

-0.10

-0.10

-0.07

-0.05

-0.08

-0.03

-0.04

-0.03

-0.02

-0.03

-0.08

-0.04

-0.05

-0.05

-0.06

-0.06

-0.04

-0.77

-0.06

-0.05

-0.05

-0.05

-0.07

-0.05

0.06

-0.05

-0.56

-0.23

0.08

-0.13

-0.17

-0.25

-0.24

-0.57

Weighted average number of common shares outstanding (basic and diluted)

98,773

192,329

95

95,717

95,650

181,676

86

86,029

71,215

65,466

60,196

60,196

60,196

91,135

49,227

42,906

40,207

32,445

32,445

32,445

32,445

32,496

27,804

27,040

27,040

27,090

27,031

27,023

23,357

22,579

22,503

18,979

12,158

-

12,004

11,506

-

-

-

Comprehensive loss:
Net loss

-8,233

-12,281

-9,669

-15,251

-8,160

-9,264

-8,756

-5,859

-3,590

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-8,441

-12,895

-9,646

-15,313

-8,177

-9,264

-8,756

-5,859

-3,590

-5,047

-1,613

-2,408

-1,700

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency translation adjustment

-826

1,135

-1,836

-1,112

312

-2

-685

-1,066

527

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-9,059

-11,146

-11,505

-16,363

-7,848

-9,266

-9,441

-6,926

-3,063

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Less: Comprehensive (loss)/income attributable to redeemable noncontrolling interest

-109

-447

-23

61

14

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss attributable to common stockholders

-8,950

-10,698

-11,482

-16,425

-7,862

-9,266

-9,441

-6,926

-3,063

-5,047

-1,613

-2,408

-1,700

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding (basic and diluted) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,444

-

-

Weighted average number of shares outstanding (basic and diluted)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,837

9,120